Anbio Biotechnology Class A Ordinary Shares (NNNN) Stock
Anbio Biotechnology Class A Ordinary Shares (NNNN) is a Healthcare stock trading at $16.60 (as of 2026-06-18), with a market capitalization of $1.50B and a trailing P/E of 234.1. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.
Anbio Biotechnology develops and supplies in vitro diagnostic products, including SARS‑CoV‑2 antigen rapid tests and SARS‑CoV‑2/influenza A/B antigen rapid tests, along with related assay platforms such as lateral flow and fluorescence immunoassays, loop‑mediated isothermal amplification, chemiluminescence immunoassays, and RT‑PCR. Its diagnostics are sold across multiple regions including the European Union, Asia Pacific, and the Americas, serving point‑of‑care, over‑the‑counter, and laboratory testing markets.